An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children

Harish Nair, Vasundhara R Verma, Evropi Theodoratou, Lina Zgaga, Tanvir Huda, Eric A F Simões, Peter F Wright, Igor Rudan, Harry Campbell

Research output: Contribution to journalArticlepeer-review

Abstract

Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, 96% of these occurring in developing countries. It is also estimated to result in about 53,000 to 199,000 deaths annually in young children. Currently there are several vaccine and immunoprophylaxis candidates against RSV in the developmental phase targeting active and passive immunization.
Original languageEnglish
Pages (from-to)S30
JournalBMC Public Health
Volume11 Suppl 3
DOIs
Publication statusPublished - 2011

Fingerprint

Dive into the research topics of 'An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children'. Together they form a unique fingerprint.

Cite this